flp-13 Antibody

What is Interleukin-13 (IL-13) and why is it a significant therapeutic target?

Interleukin-13 (IL-13) is a cytokine involved in T-cell immune responses and represents a well-validated therapeutic target for treating asthma and other allergic and inflammatory diseases. IL-13 functions by initiating signaling cascades through a ternary complex formed with two receptors: IL-13Rα1 and IL-4Rα. The importance of IL-13 as a therapeutic target is underscored by the development of several anti-IL-13 therapeutic antibodies that are currently available for clinical use in treating allergic and inflammatory conditions . Recent research has also implicated IL-13 and IL-4 signaling pathways in cancer biology, further cementing IL-13's status as a crucial therapeutic target across multiple disease states . The clinical success of anti-IL-13 antibodies demonstrates the value of targeting this pathway, while ongoing research continues to explore novel mechanisms for modulating IL-13 activity with improved specificity and efficacy.

What are single-domain antibodies (VHHs) and why are they valuable research tools?

Single-domain antibodies (VHHs), also known as nanobodies, are antibody fragments derived from camelid heavy-chain antibodies that contain only the variable domain of the heavy chain. These compact molecular entities offer significant advantages over conventional antibodies in research applications, including their small size, high stability, and capacity to access epitopes that are challenging for traditional antibodies to reach . The study described in the source material utilized a naïve llama VHH phage library to identify a diverse panel of anti-IL-13 VHHs with varying binding affinities and epitope specificities . These VHHs exhibited a wide range of affinities for IL-13, with dissociation constants (KD) spanning from low nanomolar to low micromolar values, reflecting their high CDR3 diversity . The structural simplicity of VHHs makes them excellent tools for studying protein-protein interactions, while their ability to recognize unique epitopes allows them to serve as molecular probes for investigating protein conformational states and functional domains.

What techniques are recommended for expression and purification of IL-13 for antibody research?

The expression and purification of recombinant IL-13 for antibody research requires specialized techniques due to its tendency to form inclusion bodies. Based on the research protocols, a recommended approach begins with cloning the coding region for human IL-13 (1-113) into a pET3a(+) vector and expressing in BL21(DE3) pLysS cells . For isotopically labeled protein useful in NMR studies, culture cells in modified Spizizen's minimal media containing 15N-NH4Cl and 13C-glucose; for non-labeled protein, standard LB media can be used . After inducing expression with 0.5 mM IPTG at an optical density of 0.7 at 600nm and culturing for 16 hours, harvest cells by centrifugation . The purification process then involves resuspending cell pellets in buffer (50 mM Tris-HCl, pH 8.0) supplemented with protease inhibitors, MgCl2, benzonase, and lysozyme before cell disruption at 30 kpsi . The inclusion bodies containing IL-13 should be collected by centrifugation and washed thoroughly before resolubilization in 6 M guanidine-HCl buffer containing reducing agents. Optimized refolding can be achieved through dropwise dilution into refolding buffer, followed by tangential flow filtration and size exclusion chromatography purification . This methodology typically yields properly folded, functional IL-13 suitable for antibody binding studies and functional assays.

How can researchers effectively map antibody epitopes on IL-13?

Epitope mapping of antibodies targeting IL-13 can be effectively performed using NMR-based chemical shift perturbation analysis. This technique involves monitoring changes in the 15N/1H TROSY-HSQC spectra of uniformly 15N-labeled IL-13 upon titration with unlabeled antibodies . By comparing the spectra of free IL-13 with antibody-bound IL-13, researchers can identify residues that experience significant chemical shift changes, indicating proximity to or involvement in the antibody binding site. The magnitude and pattern of these shifts provide detailed information about the epitope at atomic resolution. This approach successfully identified various epitopes on IL-13 for different VHHs, including previously unknown allosteric regulatory sites . For instance, this methodology revealed that VHH204 binds to a novel allosteric site and stabilizes IL-13 in a conformation incompatible with receptor binding . When applying this technique, researchers should prepare uniformly 15N-labeled IL-13, ensure proper sample conditions (appropriate buffer, pH, and temperature), and acquire high-quality NMR spectra with sufficient resolution to resolve individual resonances. The data analysis typically involves careful assignment of resonances and quantitative analysis of chemical shift changes to generate epitope maps that can be visualized on the three-dimensional structure of IL-13.

What cell-based assays are appropriate for evaluating IL-13 signaling inhibition?

Cell-based assays provide crucial information about the functional consequences of antibody binding to IL-13. The research described utilizes a HEK-Blue IL-4/IL-13 cell assay (InvivoGen), specifically designed to monitor the activation of the STAT6 pathway induced by IL-13 signaling . This reporter system offers a reliable method for quantifying the inhibitory effects of anti-IL-13 antibodies in a cellular context. When implementing this assay, IL-13 should be pre-incubated with each antibody at a saturating concentration (approximately 10 times the KD) before addition to the cells . The assay can generate dose-response curves, allowing determination of IC50 values for inhibition of IL-13 signaling. The research demonstrated that all tested VHHs showed complete inhibition of IL-13 signaling, with IC50 values ranging from 0.2 μM to 153.8 μM, which generally corresponded with their binding affinities . When analyzing results, it's important to include appropriate controls and to normalize data properly. Additionally, researchers should consider that inhibition in cell-based assays reflects the cumulative effect of antibody binding, including factors such as epitope location, binding kinetics, and potential conformational effects on IL-13, providing complementary information to direct binding assays such as BLI or SPR.

What novel allosteric mechanisms have been discovered for inhibiting IL-13 function?

Recent research has unveiled fascinating allosteric mechanisms for inhibiting IL-13 function, particularly through the characterization of VHH204, a single-domain antibody with unique inhibitory properties. Unlike conventional antibodies that directly block receptor binding sites, VHH204 operates through a novel allosteric mechanism by stabilizing IL-13 in a conformation that is incompatible with receptor binding - referred to as a receptor-incompetent state . NMR investigations revealed that this antibody binds to a previously unknown allosteric site on IL-13, inducing conformational changes that prevent the cytokine from properly engaging with its receptor IL-13Rα1 . This discovery has significant implications for therapeutic development, as it suggests that targeting allosteric sites can be an effective strategy for inhibiting cytokine function without directly competing with receptor binding. The study also identified several other VHHs that recognize different epitopes on IL-13, including other allosteric sites . This diversity of binding modes presents multiple opportunities for therapeutic intervention and enhances our understanding of the structural dynamics important for IL-13 function. Allosteric inhibition offers potential advantages including higher specificity and the possibility of fine-tuning inhibitory effects compared to orthosteric inhibition approaches.

How does the conformational equilibrium of IL-13 affect receptor binding and signaling?

The research has revealed a critical conformational equilibrium in free IL-13 that significantly impacts its receptor binding capabilities and signaling function. This equilibrium exists between receptor-competent and receptor-incompetent conformations, with the latter unable to effectively bind IL-13Rα1 . The discovery of this conformational flexibility provides valuable insights into the differing receptor selectivity patterns observed between IL-13 and IL-4. For IL-13, formation of the IL-13:IL-13Rα1 complex appears necessary to stabilize IL-13 in a conformation with high affinity for IL-4Rα, explaining the sequential assembly mechanism of the ternary signaling complex . This conformational control mechanism represents an important regulatory layer in IL-13 signaling. The ability of VHH204 to stabilize the receptor-incompetent state demonstrated the functional significance of this equilibrium and suggested new possibilities for therapeutic intervention . By understanding the molecular details of these conformational states, researchers can design inhibitors that selectively target and stabilize specific conformations of IL-13. This approach differs from traditional competitive inhibition strategies and may lead to more selective modulators of IL-13 activity with improved therapeutic profiles. The conformational equilibrium also explains previously observed differences in receptor binding kinetics and affinities between IL-13 and IL-4 despite their use of shared receptor components.

What insights have fragment screening approaches provided for IL-13 inhibitor development?

Fragment screening approaches have yielded groundbreaking insights for IL-13 inhibitor development, particularly through the successful application of 19F fragment screening against the IL-13:VHH204 complex. This methodology identified 40 fragments that showed binding to the complex in 19F Carr-Purcell-Meiboom-Gill (CPMG)-based NMR experiments, with 8 confirmed to bind by 1H saturation transfer difference (STD) NMR . Further characterization using 15N/1H TROSY-HSQC-based chemical shift perturbation mapping revealed three distinct fragment binding sites on IL-13 when complexed with VHH204 . The first binding site, formed by residues C29-W35 on the AB loop and residues N53-G56 on the BC loop, showed potential for allosteric modulation as fragments binding here induced chemical shift changes in residues oriented toward the interior of the helical bundle . The second site, predominantly comprising residues on helix C, presents opportunities for direct inhibition by sterically blocking interaction with IL-4Rα . The third site, involving residues at the N-terminus of helix B and C-terminus of helix C, also demonstrated potential for allosteric modulation . These fragments, with affinities in the micromolar to millimolar range, represent the first small molecules shown to bind IL-13 and provide valuable starting points for small-molecule drug discovery programs targeting the receptor-incompetent conformation of IL-13 .

What considerations are important when selecting a phage display biopanning strategy for anti-IL-13 antibodies?

When designing a phage display biopanning strategy for anti-IL-13 antibodies, several critical considerations should be addressed to maximize success. First, proper presentation of the IL-13 target is essential - the research described successfully used biotinylated IL-13 immobilized on neutravidin or streptavidin-coated plates . This approach ensures that IL-13 is presented in an accessible orientation while minimizing conformational distortion. Second, appropriate blocking and washing steps are crucial to reduce non-specific binding - the protocol utilized E-Blocking (1% BSA in PBS) for immobilizing biotinylated IL-13 and P-Blocking (2% BSA and 2% milk in PBS) for blocking phage . Third, consider the diversity of the initial phage library - the naïve llama VHH phage library used in the research yielded 30 hits that bound to IL-13, which were subsequently grouped into 16 families with significant diversity in CDR3 length (5-19 residues) and biochemical properties . Fourth, implement robust screening and validation methods - the research employed multiple rounds of biopanning followed by monoclonal ELISA assays to confirm binding specificity . Additionally, ensure proper controls are in place, such as the streptavidin-only plates used as controls to identify non-specific binders . Finally, sequence analysis of identified binders helps characterize the diversity of the antibody panel and informs selection of candidates for further characterization. This comprehensive approach enabled the identification of diverse anti-IL-13 VHHs with varying affinities, epitope specificities, and inhibitory mechanisms.

What advantages do NMR techniques offer for characterizing antibody-antigen interactions compared to other methods?

NMR spectroscopy provides distinct advantages for characterizing antibody-antigen interactions that complement other structural and biophysical methods. First, NMR delivers atomic-level resolution of binding interfaces by detecting chemical shift perturbations in backbone amide groups of 15N-labeled proteins upon antibody binding . This high-resolution mapping allows precise identification of epitopes without requiring crystallization, which can be challenging for antibody-antigen complexes. Second, NMR excels at detecting and characterizing conformational changes induced by antibody binding - the research demonstrated how VHH204 stabilizes a receptor-incompetent conformation of IL-13, a finding that might be difficult to observe with static structural techniques . Third, NMR can reveal allosteric effects that extend beyond the direct binding interface - the studies showed chemical shift changes in residues oriented toward the interior of the IL-13 helical bundle when fragments bound to surface sites, indicating potential alterations in interhelical angles . Fourth, NMR is particularly valuable for detecting weak interactions, as demonstrated in the fragment screening against the IL-13:VHH204 complex that identified hits with predicted affinities in the micromolar to millimolar range . Finally, NMR techniques can be applied to study binding kinetics and dynamics over different timescales, providing insights into conformational equilibria that are crucial for understanding protein function. These advantages make NMR an indispensable tool in the comprehensive characterization of antibody-antigen interactions, especially when investigating complex mechanisms such as allosteric regulation.

How might small-molecule inhibitors of IL-13 complement existing antibody therapeutics?

Small-molecule inhibitors of IL-13 represent a promising complementary approach to existing antibody therapeutics, offering several potential advantages. First, small molecules typically offer improved tissue penetration compared to antibodies due to their significantly smaller size, potentially reaching anatomical compartments that antibodies cannot efficiently access . Second, small-molecule drugs can usually be administered orally, which provides greater convenience for patients compared to injectable antibody therapeutics, potentially improving treatment adherence for chronic conditions like asthma. Third, the research successfully identified fragment hits that bind to allosteric sites on IL-13, suggesting the possibility of developing small molecules that stabilize the receptor-incompetent conformation identified through VHH204 binding . Such allosteric modulators might offer greater specificity than direct competitive inhibitors. Fourth, small-molecule production is typically less complex and costly than antibody manufacturing, potentially reducing treatment costs. The fragment screening approach described in the research identified the first reported small molecules shown to bind to IL-13, providing promising starting points for small-molecule drug discovery programs . The identification of three distinct binding sites on IL-13 when complexed with VHH204 suggests multiple potential mechanisms for small-molecule inhibition, including direct steric blocking of receptor binding and allosteric modulation of IL-13 conformation .

What novel approaches could further enhance the development of IL-13-targeted therapeutics?

Several innovative approaches could substantially advance the development of IL-13-targeted therapeutics based on recent research insights. First, structure-based drug design leveraging the newly identified allosteric mechanisms could yield inhibitors with improved specificity. The discovery that VHH204 stabilizes IL-13 in a receptor-incompetent conformation provides a blueprint for designing molecules that exploit this mechanism . Second, fragment-based drug discovery approaches have already identified the first small molecules known to bind IL-13, providing valuable chemical starting points for optimization . Third, the development of bispecific antibodies that simultaneously target IL-13 and related cytokines like IL-4 could provide more comprehensive pathway inhibition for inflammatory diseases. Fourth, antibody-drug conjugates that combine the specificity of anti-IL-13 antibodies with the potency of small-molecule payloads might offer enhanced therapeutic options for severe cases. Fifth, computational approaches integrating molecular dynamics simulations could help predict and design molecules that stabilize specific conformational states of IL-13. Sixth, the application of cryo-electron microscopy to visualize the IL-13 receptor complex with and without inhibitors could provide additional structural insights to guide therapeutic development. Finally, combination therapies that simultaneously target different aspects of the IL-13 signaling pathway (e.g., the cytokine itself and downstream signaling components) might offer synergistic benefits. These diverse approaches, informed by the mechanistic and structural insights from recent research, present exciting opportunities to develop next-generation therapeutics for IL-13-mediated diseases.

How can researchers integrate findings from VHH studies into conventional antibody development pipelines?

Researchers can strategically integrate insights from VHH studies into conventional antibody development pipelines through several methodological approaches. First, epitope information obtained from VHH binding studies can guide the design of conventional antibodies targeting the same regions, particularly the novel allosteric sites identified on IL-13 . The detailed mapping of VHH epitopes using NMR techniques provides precise structural information that can inform complementarity-determining region (CDR) engineering in conventional antibodies. Second, the conformational effects observed with VHHs like VHH204, which stabilizes IL-13 in a receptor-incompetent state, suggest mechanisms that could be exploited in full-size antibody design . Conventional antibodies could be engineered to induce similar conformational changes by targeting the same structural elements. Third, VHHs can serve as valuable tools in screening and characterization workflows - for example, using VHH204 to stabilize the receptor-incompetent conformation of IL-13 enabled fragment screening that identified novel small-molecule binding sites . Similar approaches could be used to screen for conventional antibodies with desired functional effects. Fourth, the modular nature of antibodies allows for the potential incorporation of VHH domains into larger antibody constructs, creating hybrid molecules that combine the unique binding properties of VHHs with the extended half-life and effector functions of conventional antibodies. Fifth, competitive binding assays between characterized VHHs and conventional antibody candidates can rapidly classify new antibodies according to their epitopes and potential mechanisms of action. These integrative approaches leverage the unique insights gained from VHH studies to enhance conventional antibody development, potentially leading to more effective and mechanistically diverse therapeutic antibodies.